TABLE 1.
Cohort characteristics
| Total | Survivors | Deceased | ||
|---|---|---|---|---|
| COVID‐19 ICU patients | n | 19 (100%) | 10 (52.6%) | 9 (47.4%) |
| Sex | Female | 1 (5.3%) | 0 (0%) | 1 (11.1%) |
| Male | 18 (94.7%) | 10 (100%) | 8 (88.9%) | |
| Age, mean (range) | 68 (47‐78) | 67.6 (47‐77) | 66 (51‐78) | |
| Comorbidities, mean (range) | 2.3 (0‐5) | 1.9 (0‐4) | 2.8 (1‐5) | |
| Hypertension | 15 (78.9%) | 9 (90%) | 6 (66.7%) | |
| Diabetes | 7 (36.8%) | 2 (28.6%) | 5 (71.4%) | |
| Obesity (BMI >30.1 kg/m2) | 11 (57.9%) | 5 (50%) | 6 (66.7%) | |
| Chronic lung disease | 4 (21%) | 1 (10%) | 3 (33.3%) | |
| Chronic ischaemic limb artery disease | 1 (5.3%) | 1 (10%) | 0 | |
| Ischaemic heart disease ‐ heart failure | 2 (10.5%) | 2 (20%) | 0 | |
| Cancer | 3 (15.8%) | 2 (20%) | 1 (11.1%) | |
| BMI (kg/m2), mean (range) | 32.3 (25.4‐46.1) | 31.1 (26.1‐37) | 33.1(25.4‐46.1) | |
| SOFA, mean (range) | 9.79 (3‐16) | 9 (5‐12) | 10.7 (3‐16) | |
| CRP (mg/L), mean (range) | 192.6 (37.8‐344.9) | 202.6 (79.1‐344.9) | 181.4 (37.8‐341.7) | |
| Creatinine (μmol/L) (range) | 118.1 (54‐213) | 101.9 (61‐194) | 136.3 (54‐213) | |
| Leucocyte count (109/L), mean | 19.97 | 27.75 | 12.21 | |
| Horowitz index (PaO2/FiO2), mean | 123.4 | 122.2 | 124.8 | |
| ECMO | Days on ECMO, mean (range) | 5 (26.3%) | 2 (20%) | 3 (33.3%) |
| 9.6 (7‐15) | 7.5 (7‐8) | 11 (7‐15) | ||
| Bacterial superinfection | n | 10 (52.6%) | 6 (60%) | 4 (44.4%) |
| Fungal infection | n | 5 (26.3%) | 3 (30%) | 2 (22.2%) |
| Antibiotic therapy | n | 17 (89.5%) | 9 (90%) | 9 (88.8%) |
| Remdesivir | 7 (36.8%) | 5 (50%) | 2 (22.2%) | |
| Dexamethasone | 8 (42.1%) | 5 (50%) | 3 (33.3%) | |
Parameters are referred to the time of ICU admission.
Abbreviations: BMI, body mass index; CRP, C‐reactive protein; ECMO, extracorporeal membrane oxygenation; SOFA, sequential organ failure assessment score.